文章摘要

TRPV2表达在结肠癌新辅助化疗中的临床意义

作者: 1马 志红, 2刘 春玲, 3卢 英军, 4王 志鹏, 2王 哲彦
1 唐山市第二医院检验科,河北 唐山 063000
2 唐山市人民医院病理科,河北 唐山 063000
3 唐山市第九医院内科,河北 唐山 063000
4 唐山市人民医院普外科,河北 唐山 063000
通讯: 马 志红 Email: 58591981@qq.com
DOI: 10.3978/j.issn.2095-6959.2019.08.004
基金: 河北省医学科学研究重点课题计划(20171317)。

摘要

目的:研究TRPV2表达在结肠癌新辅助化疗中的临床意义。方法:选择58例接受XELOX方案新辅助化疗的结肠癌患者,对患者的肠镜活检标本进行免疫组织化学染色,检测结肠癌组织中TRPV2的表达,分析TRPV2表达与患者化疗疗效及临床参数之间的关系。结果:新辅助化疗对42例(72.41%)患者有效,对16例(27.59%)患者无效;化疗有效者TRPV2表达显著高于化疗无效者(P<0.01);TRPV2表达水平与结肠癌患者的性别、年龄以及肿瘤的大小无关(P>0.05),而同肿瘤分化程度、淋巴结转移以及肿瘤浸润深度有关(P<0.05);TRPV2高表达患者5年无复发生存率低于TRPV2低表达患者(P<0.05);单因素及多因素Cox回归分析显示,TRPV2表达水平为影响结肠癌患者预后的独立危险因素。结论:TRPV2表达与结肠癌恶性生物学行为有关,对于预测结肠癌患者接受XELOX化疗方案的疗效具有一定的提示价值。
关键词: TRPV2;结肠癌;新辅助化疗

Clinical significance of TRPV2 expression in neoadjuvant chemotherapy for colon cancer

Authors: 1MA Zhihong, 2LIU Chunling, 3LU Yingjun, 4WANG Zhipeng, 2WANG Zheyan
1 Clinical Laboratory, Second Hospital of Tangshan, Tangshan Hebei 063000, China
2 Department of Pathology, Tangshan People’s Hospital, Tangshan Hebei 063000, China
3 Department of Medicine, Ninth Hospital of Tangshan, Tangshan Hebei 063000, China
4 Department of General Surgery, Tangshan People’s Hospital, Tangshan Hebei 063000, China

CorrespondingAuthor:MA Zhihong Email: 58591981@qq.com

Foundation: This work was supported by Health and Family Planning Commission of Hebei Province, China (20171317)。

Abstract

Objective: To investigate the clinical significance of TRPV2 expression in neoadjuvant chemotherapy for colon cancer. Methods: A total of 58 patients with colon cancer who received four cycles of neoadjuvant chemotherapy (XELOX regimen) were collected. Analysis on the expression of TRPV2 in the biopsy specimens (cancer tissue and pericancerous tissue) from electronic colonoscopy was carried out by immunohistochemical staining. And then the relationship between the expression of TRPV2 and the chemotherapy efficacy and clinical parameters was analyzed. Results: There were 42 cases (72.41%) with effective chemotherapy and 16 cases (27.59%) with ineffective chemotherapy. The TRPV2 score in biopsy cancer tissues of patients with effective chemotherapy was 9.21±0.55, while that of patients with ineffective chemotherapy was 4.86±0.68. The TRPV2 expression level in the effective chemotherapy group was significantly higher than that in the ineffective chemotherapy group (P<0.01). The expression level of TRPV2 was not related to the gender, age and tumor size of patients with colon cancer (P>0.05), but related to the degree of tumor differentiation degree, lymph node metastasis and tumor infiltration depth of patients with colon cancer (P<0.05). The 5-year recurrence-free survival rate of patients with high TRPV2 expression was lower than that of patients with low TRPV2 expression (P<0.05); the results of univariate and multivariate Cox regression analysis showed that TRPV2 expression level was an independent risk factor affecting the prognosis of patients with colon cancer. Conclusion: TRPV2 expression is related to the malignant biological behavior of colon cancer and affects the prognosis of patients with colon cancer. TRPV2 has certain suggestive value in predicting the efficacy of XELOX chemotherapy regimen for colon cancer patients.
Keywords: TRPV2; colon cancer; neoadjuvant chemotherapy